The Eurecat technology centre (a member of Tecnio) has developed Seleccionem, an app aimed at helping patients with multiple sclerosis choose the treatment option that best fits their preferences. The app is used in conjunction with AQuAS, a website for shared decision-making that is designed to help patients make decisions regarding the treatment of multiple sclerosis. It is estimated that more than 2 million people suffer from this disease worldwide, of whom 47,000 are living in Spain and 7,500 in Catalonia.
“These types of tool are aimed at facilitating patients’ access to reliable information that will help them make decisions regarding their healthcare”, explained Felip Miralles, the director of Eurecat’s eHealth Unit. “Patient participation is vital, as it makes it easier for us to identify needs that have yet to be met and helps us direct our efforts to improve the quality of treatment”, he continued.
“Digital transformation is bringing technological innovations that are linked to the cloud, to mobile devices, to AI and to mass data analysis, all of which help empower patients and increase the quantity and quality of their communication with healthcare professionals”, Miralles added.
This new online tool for shared decision-making aims to help those who have been diagnosed with multiple sclerosis and promote collaboration between patients and healthcare professionals, in order to provide patients with information on the advantages and disadvantages of the different treatment options. This will help reduce the impact of the disease by enabling patients to choose the approach that best meets their needs.
